NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. — Stella

Home/Breast Cancer Invasive/

View on ClinicalTrials.gov

Recruiting

Back to Breast Cancer Invasive trials

Trial locations(1 site)

China

Henan cancer hospital, Zhengzhou

Key details

Sponsor

Henan Cancer Hospital

Enrollment target

~709 participants

Started

December 2024

Primary completion

November 2026

Age range

18 Years and older

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.